ABCL

$5.88+$0.30 (+5.57%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$1.7B

305M shares

52-week range

$2.75 – $8.44

55% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-10.13

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$32M	-11.9%	$-0.57	$-0.58–$-0.56	—	5
2027	$31M	-3.4%	$-0.64	$-0.67–$-0.61	—	4
2028	$33M	+7.5%	$-0.82	$-1.00–$-0.64	—	5
2029	$64M	+91.8%	$-0.76	$-1.24–$-0.29	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-11	$-0.22	$-0.14	+36.4%
2026-02-24	$-0.18	$-0.03	+83.3%
2025-11-06	$-0.17	$-0.19	-11.8%
2025-08-07	$-0.17	$-0.12	+29.4%
2025-05-08	$-0.17	$-0.15	+11.8%
2025-02-27	$-0.15	$-0.11	+26.7%
2024-11-04	$-0.14	$-0.17	-21.4%
2024-08-06	$-0.15

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ABCLAbCellera Biologics Inc.	$5.69	+5.57%	$1.7B	—
BHVNBiohaven Ltd.	$13.82	+2.90%	$2.1B	—
CLDXCelldex Therapeutics, Inc.	$38.48	+2.60%	$2.6B	—
IMNMImmunome, Inc.	$23.08	-0.13%	$2.2B	—
JANXJanux Therapeutics, Inc.	$15.58	+4.14%

AbCellera Biologics Inc. Common Shares

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

www.abcellera.com

Employees: 562
IPO / List date: Dec 11, 2020
HQ: VANCOUVER, A1

Held by traders on TradeandTell

No one on the platform currently holds ABCL.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	1,510,629	$5.3M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ABCL yet.

$ABCL chatter on StockTwits

SuperGreenToday@SuperGreenToday1h
$ABCL Share Price: $5.70 Contract Selected: Jan 15, 2027 $5 Calls Buy Zone: $1.21 – $1.49 Target Zone: $2.30 – $2.81 Potential Upside: 80% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
Michael P@StockingtradeBullish5h
$ABCL How high we going tomorrow?!?
View on StockTwits ↗
Plan2TradeTrade2Plan@Plan2TradeTrade2Plan6h
$ABCL if this goes to $70 again, I’m moving to Vancouver! 🚀🚀
View on StockTwits ↗
Stonk Trades@StocktradesmoonBullish8h
$ABCL The market is valuing $ABCL based on what it used to be. Unpredictable research revenue. COVID-era biotech. Years of heavy spending. No approved internal medicines. But look at what is happening now: ABCL635 has entered Phase 2. ABCL575 is in Phase 1. Jazz paid $56M upfront. Vertex followed with another $28M . The company has approximately $655M of available liquidity. The risks haven’t disappeared. ABCL635 could fail, partnerships could stall and the cash burn remains significant. But AbCellera is finally approaching the period when years of investment begin producing clinical data and commercial validation. I am excited for the future.
View on StockTwits ↗
Stonk Trades@StocktradesmoonBullish9h
$ABCL When I wrote this, the Jazz partnership was my latest evidence. Now Vertex has followed. Two major pharmaceutical companies have committed $84M in combined upfront payments to access AbCellera’s T-cell engager platform while funding the partnered R&D and leaving $ABCL with milestone and royalty upside. One partnership can be dismissed as a deal. Two major partners arriving back-to-back begins to look like repeatable platform validation. The $20B thesis will not be proven by one partnership or one drug. It depends on AbCellera repeatedly creating valuable medicines for partners and for itself. Jazz was evidence. Vertex is more evidence. ABCL635 Phase 2 is the next major test. I’ll keep documenting the thesis, the numbers and the risks as the evidence develops. Follow if you’re interested in where this story goes.
View on StockTwits ↗
Stonk Trades@StocktradesmoonBullish10h
$ABCL Vertex bigger than most people think. They don’t just partner with anyone.
View on StockTwits ↗
Stonk Trades@StocktradesmoonBullish10h
$ABCL Show me a better chart than $ABCL
View on StockTwits ↗
Gracie@StrongUptrends11h
$ABCL $FBIO !!
View on StockTwits ↗
DASCorp LLC@TheDrunkTrader69Bullish12h
$ABCL reach to the heavens go baby go
View on StockTwits ↗
Adam DeMamp@DeMampCampBullish13h
$ABCL Love to see the positive movement in the 2nd half of the day, not going to overthink it though, have a wonderful rest of your evening all!
View on StockTwits ↗
Jean@oceanbleu13h
$ABCL cloing above 5.63$ on a regain of daily zone, looks like accumulation valid below. Bullish outcome so far.
View on StockTwits ↗
Bombaclaat@Rastafari13h
$ABCL finally a strong finish! Hang in there my friends!
View on StockTwits ↗
Money@Money_maker777Bullish13h
$ABCL Up we go 🚀 $QQQ $SPY
View on StockTwits ↗
John Jacobs@spud_webb13h
$ABCL is this going back to 8?
View on StockTwits ↗
Nicholas Woods@TsunamiSigma14h
$ABCL’s Vertex deal stands out more for the validation than the upfront payment. Big pharma partnerships matter because they show external confidence in the platform. The bigger test now is whether AbCellera can turn these collaborations into a repeatable growth engine.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.